Literature DB >> 14633141

The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography.

Shai Efrati1, Victor Dishy, Michael Averbukh, Alex Blatt, Ricardo Krakover, Joshua Weisgarten, Jason D Morrow, Michael C Stein, Ahuva Golik.   

Abstract

BACKGROUND: Renal failure induced by radiographic contrast agents is a known complication of coronary angiography, especially among patients with chronic renal failure. Recently, treatment with N-acetylcysteine (NAC) has been shown to have a protective effect but the mechanisms are unknown. We examined the hypothesis that NAC protected against contrast-induced renal impairment through effects on nitric oxide metabolism and oxidative stress.
METHODS: Patients with a serum creatinine concentration above 10(6) micromol/L undergoing coronary angiography were randomly assigned to receive either NAC 1 g (N= 24) or placebo (N= 29) twice daily 24 hours before and after angiography with 0.45% saline hydration in a double-blind study. Creatinine clearance was calculated and urinary nitric oxide and F2-isoprostane excretion were measured at baseline, 24 and 96 hours after angiography.
RESULTS: Treatment with NAC significantly improved the effect of contrast media on creatinine clearance, and maximal beneficial effect was observed 24 hours after angiography. Creatinine clearance (mL/min) was 59.5 +/- 4.4, 64.7 +/- 5.8, and 58.7 + 3.9 at baseline, 24, and 96 hours after angiography in the NAC group, respectively, and 65.2 +/- 3.2, 51.5 +/- 3.7, and 53.6 +/- 3.9 in the placebo group, respectively (P < 0.0001). NAC treatment prevented the reduction in urinary nitric oxide after angiography. The urinary nitric oxide/creatinine ratio (micromol/mg) was 0.0058 +/- 0.0004, 0.0057 +/- 0.0004, and 0.0052 +/- 0.0004 at baseline, 24, and 96 hours after angiography in NAC group, respectively, and 0.0057 +/- 0.0007, 0.0031 +/- 0.0005, and 0.0039 +/- 0.0005 in the placebo group, respectively (P= 0.013). NAC had no significant effect on urinary F2-isoprostanes.
CONCLUSION: NAC treatment has renoprotective effect in patients with mild chronic renal failure undergoing coronary angiography that may be mediated in part by an increase in nitric oxide production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633141     DOI: 10.1046/j.1523-1755.2003.00322.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Does the prophylactic use of N-acetylcysteine prevent contrast nephropathy in patients with renal insufficiency?

Authors:  Irene Wai Yan Ma; Michelle Hladunewich
Journal:  CMAJ       Date:  2004-04-13       Impact factor: 8.262

Review 2.  How to protect from contrast media-induced nephropathy?

Authors:  B Scheller
Journal:  Clin Res Cardiol       Date:  2007-03       Impact factor: 5.460

3.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

4.  Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.

Authors:  Yao-Min Hung; Shoa-Lin Lin; Shih-Yuan Hung; Wei-Chun Huang; Paul Yung-Pou Wang
Journal:  World J Cardiol       Date:  2012-05-26

5.  Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease.

Authors:  Mochammad Thaha; Mohammad Yogiantoro; Yasuhiko Tomino
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

6.  N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients.

Authors:  Tariq Rehman; Jason Fought; Richard Solomon
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

Review 7.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

8.  N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.

Authors:  Manouchehr Amini; Mojtaba Salarifar; Alireza Amirbaigloo; Farzad Masoudkabir; Fatemeh Esfahani
Journal:  Trials       Date:  2009-06-29       Impact factor: 2.279

Review 9.  Contrast-Induced Nephropathy: A Review of Mechanisms and Risks.

Authors:  Elham Shams; Harvey N Mayrovitz
Journal:  Cureus       Date:  2021-05-04

10.  A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity.

Authors:  Denise A Gonzales; Kelly J Norsworthy; Steven J Kern; Steve Banks; Pamela C Sieving; Robert A Star; Charles Natanson; Robert L Danner
Journal:  BMC Med       Date:  2007-11-14       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.